Skip to Content
MilliporeSigma
All Photos(2)

Documents

HCMP2MAG-19K

Millipore

MILLIPLEX® Human Complement Panel 2 - Immunology Multiplex Assay

The Human Complement Panel 2 Bead-Based Multiplex Assay kit, using the Luminex xMAP technology, enables the simultaneous analysis of complement proteins and factors in human serum, plasma and cell culture samples.

Synonym(s):

Human complement multiplex kit, Luminex® human complement immunoassay, Millipore human complement panel

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.47

Quality Level

200

species reactivity

human

manufacturer/tradename

Milliplex®

assay range

accuracy: 95%
(Complement C3)
sensitivity: 0.024 ng/mL
(Complement Factor B)
sensitivity: 0.048 ng/mL
(Complement C1q)
sensitivity: 0.120 ng/mL
(Complement C3)
sensitivity: 0.135 ng/mL
(Complement Factor H)
sensitivity: 0.191 ng/mL
(Complement C4)
sensitivity: 3.639 ng/mL
(Complement C3b/iC3b)
standard curve range: 0.041-300 ng/mL
(Complement Factor H)
standard curve range: 0.08-60 ng/mL
(Complement C1q)
standard curve range: 0.08-60 ng/mL
(Complement Factor B)
standard curve range: 0.27-200 ng/mL
(Complement C3)
standard curve range: 0.55-400 pg/mL
(Complement C4)

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex xMAP)

shipped in

ambient

Related Categories

General description

The complement system consists of many plasma proteins that assist the ability of phagocytic cells and antibodies to clear pathogens. There are three different simultaneous pathways. The classical pathway is stimulated by antigen-antibody complexes; the alternative pathway spontaneously activates on contact with pathogenic cell surfaces; and the mannose-binding lectin (MBL) pathway recognizes mannose sugars usually present only on pathogenic cell surfaces. Because of the potential to be extremely damaging to host tissues, complement system activation must be tightly controlled. The regulating complement control proteins, including CD59, also known as protectin, are present at a higher concentration in the blood plasma than the complement proteins themselves. The complement system is thought to play a key role in many diseases with an immune component, such as asthma and many autoimmune diseases, including SLE, IBD and multiple sclerosis. It is also becoming increasingly associated with neurological disease, such as Alzheimer′s disease and conditions such as spinal cord injuries.

MILLIPLEX® Complement Panel 2 Bead Panel is a six-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma or culture supernatant samples: C1q, C3, C3b/iC3b, C4, Complement Factor B, Complement Factor H and Properdin.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Immune Response

Specificity

Cross Reactivty
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Application

  • Analytes: C1q, C3, C3b/iC3b, C4, Factor B, Factor H
  • Recommended Sample type: Serum, plasma, and tissue/cell culture supernatant
  • Recommended Sample dilution: 1:40,000 diluted plasma or serum. Tissue culture supernatant may require a dilution with an appropriate control medium prior to assay
  • Assay Run Time: Overnight or two-hour primary incubation
  • Research Category: Inflammation & Immunology
  • Research Subcategory: Inflammation
  • Note: To avoid complement activation in samples, which will affect the results, samples should be thawed as rapidly as possible, put on ice and assayed immediately

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

Packaging

96 well plate

Storage and Stability

Recommended storage for kit components is 2 - 8°C.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

Storage Class

10 - Combustible liquids

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pavan Bhargava et al.
Multiple sclerosis (Houndmills, Basingstoke, England), 27(4), 509-518 (2020-07-17)
Synaptic loss is a feature of multiple sclerosis pathology that can be seen even in normal-appearing gray matter. Opsonization of synapses with complement components may underlie pathologic synapse loss. We sought to determine whether circulating neuronal-enriched and astrocytic-enriched extracellular vesicles
Manjunath Ramanjaneya et al.
Frontiers in endocrinology, 13, 918320-918320 (2022-08-02)
Complement factors mediate the recruitment and activation of immune cells and are associated with metabolic changes during pregnancy. The aim of this study was to determine whether complement factors in the maternal serum and follicular fluid (FF) are associated with
Laura McCulloch et al.
F1000Research, 8, 1039-1039 (2019-11-12)
Background: Blockade of the cytokine interleukin-1 (IL-1) with IL-1 receptor antagonist (IL-1Ra) is a candidate treatment for stroke entering phase II/III trials, which acts by inhibiting harmful inflammatory responses.  Infection is a common complication after stroke that significantly worsens outcome
Milla R McLean et al.
Clinical & translational immunology, 10(11), e1355-e1355 (2021-11-13)
Tuberculosis comorbidity with chronic diseases including diabetes, HIV and chronic kidney disease is of rising concern. In particular, latent tuberculosis infection (LTBI) comorbidity with end-stage kidney disease (ESKD) is associated with up to 52.5-fold increased risk of TB reactivation to
Manjunath Ramanjaneya et al.
Frontiers in endocrinology, 12, 641361-641361 (2021-04-17)
Gestational Diabetes Mellitus (GDM) development is related to underlying metabolic syndrome that is associated with elevated complement C3 and C4. Elevated C3 levels have been associated with preeclampsia and the development of macrosomia. This case-control study included 34 pregnant women
View All Related Papers

Related Content

Immunology Multiplex Assays | MILLIPLEX®

Immunology multiplex assays like MILLIPLEX® allow simultaneous investigation of immune biomarkers, saving time and resources in research.

Overview of Luminex® Multiplex Assay Technology | MILLIPLEX® Multiplex Assays

Discover the benefits of MILLIPLEX® multiplex assays, based on Luminex® xMAP® multiplex assay technology, that provide consistent, high-quality results and see how these multiplex biomarker Luminex® assays are being used to advance research.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service